A study was carried out in 7 patients with chronic obstructive airways disease to investigate the possibility of serious cardiovascular effects after the intravenous infusion of salbutamol. Patients received salbutamol starting at 5 micrograms/min and increasing gradually to 20 micrograms/min. There results of blood gas analysis showed that all but one of the patients were hypoxic and there was evidence of improved ventilation at the end of the first hour of infusion in most, with a mean reduction of 0.43 kPa in PaCO2. The patients' ECGs were monitored continuously before and during the infusion. There was an increase in mean heart rate, but not significant arrhythmias clearly provoked by salbutamol were seen. It is concluded that these findings indicate that any cardiovascular risks with parenteral salbutamol are negligible.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Home high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial.
BMJ Open Respir Res
January 2025
Lane Fox Clinical Respiratory Physiology Research Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Introduction: Patients recovering from severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have a 30-day readmission rate of 20%. This study evaluated the feasibility of conducting a randomised controlled trial to evaluate clinical, patient-reported and physiological effects of home high-flow therapy (HFT) in addition to usual medical therapy, in eucapnic patients recovering from AECOPD to support the design of a phase 3 trial.
Methods: A mixed-methods feasibility randomised controlled trial (quantitative primacy, concurrently embedded qualitative evaluation) (ISRCTN15949009) recruiting consecutive non-obese patients hospitalised with AECOPD not requiring acute non-invasive ventilation.
Pharmacological Interventions for the Acute Treatment of Hyperkalaemia: A Systematic Review and Meta-analysis.
Resuscitation
January 2025
Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address:
Background: Hyperkalaemia is a life-threatening electrolyte disturbance and also a potential cause of cardiac arrest. The objective was to assess the effects of acute pharmacological interventions for the treatment of hyperkalaemia in patients with and without cardiac arrest.
Methods: The review was reported according to PRISMA guidelines and registered on PROSPERO (CRD42023440553).
Influence of the ERK/CHGB Pathway in Breast Cancer Progression Under Chronic Stress.
Int J Biochem Cell Biol
January 2025
Oncology Department, Yan 'an Hospital of Kunming Medical University, Kunming, Yunnan, China.
Background: Breast cancer is one of the most common malignancies among women, and its development involves a variety of complex molecular mechanisms. Extracellular signal-regulated kinase (ERK) and Chromogranin B (CHGB) are known to play key roles in various cancers. This study aims to explore the impact of the ERK/CHGB pathway in a chronic stress environment simulated by salbutamol on the development of breast cancer.
View Article and Find Full Text PDFCombination Inhaled Corticosteroid and Short-acting Beta2 Agonist (ICS-SABA) Use for Older Adults With Asthma.
Sr Care Pharm
January 2025
2 Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas.
The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used.
View Article and Find Full Text PDFAs-Needed Inhaled Corticosteroid-Formoterol in a Single Inhaler Compared to Inhaled Corticosteroid-Albuterol in Separate Inhalers as Reliever Therapy in Mild Pediatric Asthma: A Cost-Utility Analysis.
Pediatr Pulmonol
December 2024
Department of Pharmacology and Toxicology, School of Medicine, Research Group in Pharmacology and Toxicology (INFARTO), Universidad de Antioquia, Medellín, Colombia.
Objectives: Since 2019 as-needed low-dose ICS-formoterol in a single inhaler has been recommended for treatment of mild asthma in children aged more than 12 years. Alternatively, the use of ICS-albuterol has been proposed in countries where ICS-formoterol is not available or affordable. The aim of the present study was to evaluate the cost-utility of as-needed ICS-albuterol in separate inhalers compared to ICS-formoterol in a single inhaler as reliever therapy in pediatric patients with mild asthma living in Colombia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!